How to be a successful biotech CEO: insights from Mark Corrigan M.D.

What makes a biotech CEO truly effective in the boardroom? In this episode of #BIOfromtheBAYOU, host Elaine Hamm, PhD, talks with biotech board veteran Mark Corrigan, MD, who has served on and led boards across the industry. He shares candid insights on what boards look for in CEOs, the pitfalls to avoid, and how leadership qualities like humility and adaptability drive success in biotech. 🎙️ Tune in to gain insider perspectives on board dynamics and biotech leadership strategy: https://ow.ly/g6bX50WUAR0 #Biotech #Leadership #KeyOpinionLeader #BoardOfDirectors #LifeSciences

Biotech funding has shifted massively. Old playbooks no longer apply, and investors have become far more selective. Today, leadership teams are judged less on their promises and more on their proven ability to navigate regulatory hurdles, build commercial pathways, and successfully bring products to market. In our latest blog, we break down what this means for biotech founders and the types of leadership experience investors are prioritising in 2025. Follow the link in the comments to read the full piece.

#UncodedUnplugged | Episode 4 🎥🎙️ The Code of Trust: Empowering Science Through Partnerships 🤝 In this episode, sunil vats, Head of Business Development at Uncoded, articulates how his team reimagines sales - not by pushing solutions, but by understanding scientists’ challenges and shaping precise strategies to solve them. By demystifying multi-omics and aligning solutions with research goals, they empower lasting partnerships and meaningful impact. 🧬 #Uncoded #DNAAndBeyond #MadeInIndia #Genomics #Leadership #Business #PremasLifeSciences #NGS #Multiomics

🤔 Another standout clip from this week’s penultimate episode of Leading Beyond the Lab Season 3, featuring Normunity’s powerhouse leadership duo – Rachel W. Humphrey, MD and Melinda Merchant. 🎙️ In this moment, they reflect with Lawrence Rose on how to lead high-performing teams across biotech, big pharma, and academia - while keeping momentum and mutual respect intact. “The most important conversations start with: ‘I wouldn’t do it that way.’ And instead of pushing back, we say, ‘Tell me why.’ That’s where real science starts.” It’s a rare inside look at biotech leadership that builds trust, unlocks creativity - and gets real results. 👉 Click to watch or listen to the full conversation - https://lnkd.in/dqTBAshA

The future of life sciences demands leaders who move beyond familiar archetypes. It will be shaped by those who anticipate regulatory change, guide transformation, and deliver measurable impact under pressure. In her latest article, our Founder, Chairman & CEO, Denise (DeeDee) DeMan, explores how organizations can: 🔹Build future-ready CEO pipelines 🔹Avoid the risks of narrow succession planning 🔹Unlock transformational value with precision leadership alignment 🔗 Read the full article here: https://lnkd.in/gSBqGihF What qualities do you believe are most critical for the next generation of CEOs? We’d love to hear your thoughts. #LifeSciences #Leadership #Biotech #Pharma #ExecutiveSearch #Innovation #DrugDevelopment #ExecutiveLeadership #BoardGovernance #Biotechnology #SuccessionPlanning

Earlier this year, Dr. Judy Chou had the privilege of serving as a panelist at the 11th Annual American Biomanufacturing Summit in San Francisco. She shared her perspectives on the pivotal role of digitalization in streamlining biomanufacturing processes and accelerating the delivery of vital treatments to patients. If you missed her talk, you can catch the highlights in this interview: https://lnkd.in/g4qTBpfE #AmericanBiomanufacturing #GenerisBio #digitalization #leadership #JudyChou

Under Pressure, Leaders Rise When I spoke with Cyrill Kellerhals, COO of Andelyn Biosciences, I was struck by how calm and grounded he was while describing some of the toughest leadership moments of his career. At Novartis, one of the industry’s legendary companies, he encountered the kind of regulatory challenge that every leader dreads — a moment that could define the company’s future. Instead of panicking, he led his team through it and turned it into a success. Later, he carried those lessons into scaling a $34M operation and building a $200M biopharma facility. But what impressed me most wasn’t the numbers — it was the way he talked about leading with humility, purpose, and service to his people. His story is a reminder that real leadership isn’t about avoiding pressure. It’s about how you show up when the stakes are highest. 👉 What’s one trait that separates good from great leaders under pressure?

The playbook for biopharma global expansion has fundamentally changed. Our new research reveals how industry leaders are shifting from large-scale buildouts to leaner, partnership-driven models in response to economic uncertainty and complex market access challenges.   Based on interviews with 14 European/international GMs and presidents, learn how high-growth biopharma companies are prioritizing capital efficiency while making critical early leadership decisions that determine commercial success and optimize patient impact: https://bit.ly/3HZhX0P

The playbook for biopharma global expansion has fundamentally changed. Our new research reveals how industry leaders are shifting from large-scale buildouts to leaner, partnership-driven models in response to economic uncertainty and complex market access challenges.   Based on interviews with 14 European/international GMs and presidents, learn how high-growth biopharma companies are prioritizing capital efficiency while making critical early leadership decisions that determine commercial success and optimize patient impact: https://bit.ly/3HZhX0P

The playbook for biopharma global expansion has fundamentally changed. Our new research reveals how industry leaders are shifting from large-scale buildouts to leaner, partnership-driven models in response to economic uncertainty and complex market access challenges.    Based on interviews with 14 European/international GMs and presidents, learn how high-growth biopharma companies are prioritizing capital efficiency while making critical early leadership decisions that determine commercial success and optimize patient impact: https://bit.ly/3HZhX0P Neil HughesMargarida DuarteAlexey KutahovJean-Yves ChatelanLee HeesonGeorg Pirmin MeyerPetra Molan, PharmD MScOrlando OliveiraThomas A. LacknerSamer SaadehLaura GenatossioAnant Murthy, PhDSebastian StachowiakGerwin Winter